mic function in children and young adults. 3, 4 The reduction of CD4 ϩ T cells might also be caused or aggravated by excessive peripheral destruction mediated by monocytes through Fas/Fas ligand interactions. 5 In addition, the immune defect in the post-transplant period involves defective antigen presentation. It has been reported that the patients' accessory cells fail to stimulate proliferation and IL-2 secretion by normal allogeneic T cells in MLR reactions suggesting that the patients' antigen-presenting cell (APC) populations are abnormal either numerically or functionally. 6 Dendritic cells (DC) constitute the most powerful APC population. DC are uniquely defined by their ability to prime naive T cells and to induce strong immune responses (for recent reviews see Refs 7 and 8) . DC are highly enriched among cells expressing MHC class II antigens such as HLA-DR that lack the markers of other leukocytes collectively referred to as lineage (lin) markers. In blood, this lin Ϫ HLA-DR ϩ cell population can be further segregated by differential expression of markers such as CD11c, CD4, CD5, CD33 or CD2. A number of studies [9] [10] [11] [12] [13] have collectively defined two subpopulations of circulating blood DC both of which are lin Ϫ , HLA-DR ϩ . One, with the phenotype CD11c ϩ , CD33 ϩϩ , CD2 ϩ , CD4 low , IL-3R␣ ϩ , is a potent APC with the ability to activate naive T cells. The other, with the phenotype CD11c Ϫ , CD33 +low , CD2
ϩϩ is a less potent APC when tested in MLR and it requires in vitro maturation to acquire strong T cell stimulatory function. The latter population of DC contains cells described as plasmacytoid T cell-DC or pDC2 for their ability to stimulate Th2-like T cell responses 14 and are also known as natural interferon-producing cells for their ability to produce large amounts of type 1 interferon. 15 These studies have therefore shown that the differential expression of the beta 2 integrin CD11c on lin Ϫ HLA-DR ϩ blood cells is a useful marker to discriminate between functionally distinct subsets of DC. As several subsets of DC are being defined, it is predictable that disruptions in their homeostasis could have significant consequences on immunity. Yet, little is known of the mechanisms that regulate the formation of the various types of APCs in vivo particularly under regenerative circumstances. Circulating blood levels of DC are low, but it is possible to reliably measure such cells by flow cytometry in normal individuals where lin Ϫ HLA-DR ϩ cells constitute 0.75 to 0.85% of mononuclear cells (MNC). 16, 17 The impact of chemotherapy on numbers of circulating DC is unclear. There are reports that chemotherapy and particularly HDC reduces levels of circulating lin Ϫ HLA-DR ϩ DC. 16 Another study, measuring DC by
Bone Marrow Transplantation expression of the specific marker CMRF44 after a short in vitro incubation, found that the levels of DC were normal after autologous transplantation but that patients suffering from acute GVHD after allogeneic transplantation had reduced levels of DC. 17 The time course of DC recovery is unclear and it is not known if the composition of DC subsets is affected during hematopoietic recovery.
We were able to analyze a small cohort of patients transplanted with purified CD34 ϩ cell autologous transplants for the treatment of metastatic breast cancer. Such purified autografts are highly depleted of contaminating tumor cells and of mature cells but contain hematopoietic stem cells and progenitor cells that provide a rapid and sustained recovery of granulocytes, platelets and lymphocytes. 18 However, following purified CD34 ϩ cell autografts there is a significantly longer delay in the recovery of naive CD4 + T cell levels compared to unmanipulated autografts, suggesting that the lack of mature cells in the purified transplant delays the return to normal T cell homeostasis. 19 The regenerative capacity of naive CD8
+ T cells and of DC subsets has not been evaluated after autologous transplant of CD34 ϩ cell-selected grafts. We analyzed blood levels of lymphocytes and of APC subsets in these patients using multi-parametric definitions of the cell subsets by flow cytometry. Our results confirm the persistent reduction of naive CD4
ϩ T cells and show a reduction of naive CD8 + T cells. There is a rapid recovery of DC subsets but an abnormal contribution of CD11c Ϫ cells.
Materials and methods

Patients
Six patients from 34 to 60 years old (all female, median 42.5 years old), with metastatic breast cancer involving multiple bone metastasis or with the presence of breast cancer cells in bone marrow by routine microscopy, received autologous CD34 ϩ cell transplantation at the Karmanos Cancer Institute (Table 1) . Purified CD34 ϩ cells were prepared from PBPC using the standard Isolex 300i protocol /l (usually 7-11 days). The clinical protocol was approved by the Institutional Review Board of Wayne State University. After patients' informed consent, heparinized venous blood was collected at days 42, 126 and 168 post transplantation. At the same time, blood was also sampled separately for total and differential leukocyte counts. Mononuclear cells (MNC) were prepared from heparinized blood after centrifugation over Ficoll (Pharmacia Biotech, Piscataway, NJ, USA) and cryopreserved in autologous plasma and 10% DMSO (Sigma, St Louis, MO, USA) for future analysis. Table 1 indicates when samples were obtained for each patient.
Controls
For normal controls, we collected blood from healthy adult volunteers (n ϭ 9, three males and six females, 21-74 years old, median ϭ 25 years old) with their consent, and processed the MNC in the same conditions as patient samples.
Flow cytometry analysis of multi-color immunostaining
MNC were thawed quickly in a cold solution of RPMI1640 containing heparin (10 units/ml) (Sigma) and deoxyribonuclease (10 g/ml) (Boehringer Mannheim, Indianapolis, IN, USA), washed twice and counted. Non-specific Fc binding was blocked by addition of 10 g human gamma globulin/10 5 cells for 10 min on ice (Gamimune; Miles, Eckhart, IL, USA). Approximately 2 ϫ 10 5 cells were placed per well of 96-well V-bottom plates and incubated with directly labeled monoclonal antibodies (mAbs) ( Table  2) for 40 min. For three-color analysis we used combinations of fluorescein (FITC), phycoerythrin (PE) and tricolor (TC)-conjugated mAbs. For four-color analysis, we used a combination of FITC, PE, peridin chlorophyll protein (per-CP) and allophycocyanin (APC)-conjugated antibodies. Cells were then washed twice in PBS ϩ 0.2% bovine serum albumin ϩ 0.02% sodium azide before being analyzed on a FacScan instrument (Becton Dickinson, San Jose, CA, USA). Live cells were defined by appropriate forward scatter (FSC) and side scatter (SSC). Negative controls included directly labeled IgG1 and IgG2a irrelevant mAbs were used to determine the boundaries of regions in two-color dot plots such that Ͼ98% of the cells would be located in the appropriate regions. Flow cytometric data were obtained after acquisition of a minimum of 10 000 events.
Data analysis
Flow cytometric analysis was done using PC lysis software (Becton Dickinson). For statistical analysis the MannWhitney rank sum test was implemented with the SigmaStat software.
Results and discussion
We studied a small cohort of metastatic breast cancer patients treated with HDC and autologous purified CD34 ϩ cells (Table 1) . We determined the percentages of various subsets of immune cells in the mononuclear cell (MNC) fraction of blood that was cryo-preserved at days 42, 126 
Recovery of APC subsets
Circulating monocytes are endowed with limited antigenpresenting cell (APC) capability but constitute a reservoir of precursor cells able to give rise to 'professional' antigenpresenting dendritic cells (DC). 22 Monocyte levels were at normal levels at all time points examined after transplantation (Figure 1 ). Monocytes were identified with flow cytometry by their low expression of CD4 with low SSC and intermediate FSC characteristics and we verified that these cells co-expressed the CD14 monocyte marker (data not shown). To detect the much rarer APC population of DC we analyzed the lineage (lin)
Ϫ HLA-DR ϩ population of blood MNC which is enriched for DC. The lack of lin markers was defined with antibodies against CD14, CD15, CD16, CD3, CD19 and CD34 to exclude respectively mature monocytes, granulocytes, NK cells, T cells, B cells and progenitor cells. We included anti-CD34 mAbs in our panel of 'lineage' antibodies to ensure the exclusion of circulating hematopoietic progenitor cells which could possibly persist after transplantation. The presence of lin Ϫ HLA-DR ϩ cells was readily detectable by three-color flow cytometry in the MNC of controls and patients. In our hands, the average percentage of lin Ϫ HLA-DR ϩ cells in control MNC was 0.7 Ϯ 0.15%, a value that is similar to the values reported for normal blood samples by Fearnley et al 17 (0.85% of MNC) and by Savary et al 16 (0.75% of MNC Ϯ 0.04%) thus validating our experimental approach. We found that the population of lin Ϫ HLA-DR ϩ cells was elevated in patients (patients 1-5, median ϭ 1.9%, 1.34%, 2.14% of MNC, respectively, at days 42, 126 and 168) compared to controls (median ϭ 0.63% of MNC, n ϭ 5). The difference is significant (P ϭ 0.01) at day 42. In patients, the absolute number of lin Ϫ HLA-DR ϩ cells was on average 36.7 Ϯ 28 per l of blood (median ϭ 33 per l; range 0-81 per l) which seems to be higher than the average normal adult blood value of 19.8 per l calculated from Fearnley's data 17 and higher than the value of 5.4 Ϯ 3.2 per l reported for cord blood. 23 Further analysis of the DC population was made to determine if there were differences in DC subset composition. The DC-specific marker CD83 was not useful because of the low intensity of staining in steady-state non-activated cells as noted by others. 17 We avoided the use of markers requiring ex vivo activation as we felt this might lead to technical difficulties in cryopreserved samples and might cause problems with interpretation of the data. The lin calculated in six patient samples and found to be 3.8 Ϯ 4.8 per l. This value is close to the value of 9.8 CMRF44 ϩ DC per l of normal blood 17 although it is not known if these two DC subsets overlap entirely.
The composition of the APC population appears to be modified by PBPCT. We found significantly higher levels of lin Ϫ HLA-DR ϩ CD11c Ϫ cells on day 42 than in controls (Figure 1 ). In the patient group on day 42 , lin Ϫ HLA-DR ϩ CD11c Ϫ cells averaged 2.03 Ϯ 0.99% of MNC vs 0.53 Ϯ 0.12% of MNC in the control group. Cells with this CD11c Ϫ phenotype have been described as 'immature' DC with low T cell-stimulating capacity 9 and thus might contribute to some of the defective APC function that has been described post transplantation. 2 Further work is needed to investigate the function of these CD11c
Ϫ cells in the posttransplant period. Unlike normal adult blood, CD11c
Ϫ cells represent the majority of lin Ϫ HLA-DR ϩ cells in cord blood 23 suggesting that ontogeny-related changes, that could possibly be recapitulated after PBPCT, might affect the composition of the DC population. The ontogenic origin of such CD11c Ϫ IL3R␣ ϩ DC remains unclear, as they may be myeloid 24 or lymphoid. 25 Our preliminary experiments using four-color flow cytometry confirmed the presence of lin Ϫ CD4 ϩ CD11c Ϫ IL3R␣ ϩ in several patient samples (data not shown). However, these cells represented only a fraction of lin Ϫ HLA-DR ϩ CD11c Ϫ and were not systematically elevated (data not shown). It is therefore unclear if all CD11c Ϫ lin Ϫ HLA-DR ϩ cells are APCs. Further analysis of a larger number of patient and control samples with additional combinations of antibodies will be required to clarify this question. Thus, in spite of possible changes in the composition of the DC population, our results suggest that the homeostasis of circulating DC is rapidly achieved in regenerative circumstances after CD34 ϩ PBPCT. These results seem to conflict with an earlier study of a small number of patients that showed reduced levels of DC after chemotherapy 16 but the results might be explained by differences in the treatment regimens between the two studies. Our results concur with another flow cytometric study which characterized DC with a different antigen, CMRF44 and which observed that normal levels of DC could be obtained less than 60 days after autologous transplantation. 17 We show that normal levels of CD11c ϩ DC are obtained at, and perhaps before, day 42 post transplantation of purified CD34 ϩ cells.
Lymphocytes
In the same groups of patients and controls that were analyzed in Figure 1 , we determined levels of lymphocytes. Levels of B cells (defined by expression of the pan-B cell marker CD19), of natural killer cells (NK) cells (defined by expression of CD56 and lack of CD3) and of T cells (defined by expression of the T cell receptor ␣␤ chains) were not significantly different between controls and patients ( Figure 2 ) (P Ͼ 0.05 at each of the time points examined). Thus, we confirm that transplantation of CD34 ϩ cell-selected autografts did not impair the return of T, B and NK lymphocytes evaluated as whole cell populations. 19 The unusual subset of T lymphocytes expressing the TCR␣␤ but lacking the co-accessory molecules CD4 or CD8 has potential suppressor activity and was reportedly elevated after autologous transplantation of GM-CSF-mobilized whole peripheral blood. 26 In our study, some patients had high levels of double negative T cells at early time points (day 42), but overall, these did not reach statistical significance. We found a marked and significant reduction in CD4
ϩ T cells (defined by the three-color phenotype CD4 ϩ CD8 Ϫ TCR␣␤ ϩ ) as has been widely reported after chemotherapy and transplant. 2 In contrast, the population of CD8 ϩ T cells expressing CD8 and the TCR␣␤ but lacking CD4 was significantly elevated on day 42 (P Ͻ 0.05) but returned to normal at later time points.
Naive T cells
Few data exist on levels of naive CD8 ϩ T cells in regenerative circumstances. The population of CD8 ϩ T cells expressing CD45RA was not significantly different from controls at any time point (not shown). However, this phenotype does not exclusively define naive CD8 T cells. Cells with the functional characteristics of naive CD8 ϩ T cells coexpress CD45RA as well as other markers such as CD27. 27 We measured levels of naive CD8
by four-color immunostaining in a group of five patients (patients 1, 2, 3, 5, 6) and in six normal controls. As shown in Figure 3 , patients had significantly reduced naive CD8
ϩ T cells as well as naive
Bone Marrow Transplantation CD4 ϩ T cells. It is important to note that naive CD8 ϩ T cells albeit low, were usually detectable whereas naive CD4 ϩ T cells were sometimes undetectable and thus appear to be more profoundly affected. It is known that the production of naive T cells is age-related and decreases in individuals older than 35 years. 28 Differences in the ages of the patients studied (median age ϭ 43 years old, extremes 42-60 years old) and in the ages of controls (median age ϭ 30 years old, extremes 22-74 years old) may give the ϩ T cells and naive CD8
ϩ T cells among blood MNC using four-color flow cytometry. The analysis was done on a different set of control (n ϭ 6) and patient samples (patients 1, 2, 3, 5, 6) than represented in Figure 1 . Naive CD4 impression that naive T cell levels are low in patients post PBPCT. However, a study by Roederer et al 28 of a group of individuals that is more closely aged-matched to our patients (36-50 years old) shows that their absolute naive CD4 ϩ and CD8 ϩ T cell counts are approximately 130 per l and 300 per l, contrasting with our patients' values of 13 ± 14 naive CD4 + T cells per l and 40 Ϯ 22 naive CD8 ϩ T cells. This suggests that our patients are indeed deficient in naive T cells. This lack of naive T cells is consistent with other studies that showed a profound lack of naive CD4 ϩ T cells after CD34 ϩ cell PBPCT 19 and suggested that intensive chemotherapy lowered the levels of naive CD8 ϩ T cells in children and young adults. 4 The combined lack of naive CD4 ϩ and CD8 ϩ T cells suggests that there is a problem at the level of production. Thus, in spite of a seemingly rapid return to 'normal' counts of lymphocytes post PBPCT, the majority of circulating T cells post HDC and PBPCT is activated rather than naive. This lack of naive T cells predicts that it will be difficult to elicit immune responses against novel antigens in the post PBPCT period. Optimistically, the detection of a few naive T cells suggests that mechanisms could be found to improve their production.
In conclusion, we show that DC recover rapidly post CD34 ϩ PBPCT. The presence of normal levels of circulating CD11c ϩ DC is concordant with the rapid recovery of monocytes and with the concept that CD11c ϩ DC are of myeloid origin. 13 In contrast, the recovery of naive T lymphocytes is delayed for at least 6 months. A better understanding of the homeostasis of immune cells in defined circumstances will provide important information to guide strategies of immunotherapy in the setting of HDC and transplantation.
